Cannabis Science Inc (OTCMKTS:CBIS) a company specializing in the formulation of cannabis-based medicine, stated presentation of a U.S. Senate bill that promises to end the federal prohibition on medical marijuana as a common sense initiative. It will contribute to advancement of new science-based research. The company also termed it as a science based blessing for people suffering from debilitating diseases across the U.S.
The bill
The bi-partisan bill was presented at a press conference by Senators Kirsten Gillibrand, Rand Paul and Cory Booker. The bill would downgrade medical pot Drug Enforcement Agency categorization to Schedule 2 from Schedule 1, allowing physicians to recommend it to some patients like several veterans in need. Cannabis Science stated that the move will enable more advance research and ease banking problems in providing basic services to the marijuana industry.
The views
Sen Paul said that it the emotion of the tugs at people’s heart. Other Senator Gillibrand said that it is a medical treatment with effective results. Raymond C. Dabney, the Co-Founder, President and CEO of Cannabis Science Inc (OTCMKTS:CBIS) said that this is history. It is the best chance yet to get on with the measures of relieving the suffering of patients and veterans and children across the U.S. The legislation needs modification to promote research, to bring significant investment into the field and to assist people who are in need of these medicines.
The takeaway
The CEO of Cannabis further added that he highly recommend to give some time to watch the highlights of conference so that everyone can know the need of medical marijuana. The need is stated directly for parents as well as patients who said that they received relief by using medical cannabis. In last trading session, the stock price of Cannabis Science dropped 6.15% to close the trading session at $0.0336 on share volume of 6.16 million.
